30.92
+1.52(+5.17%)
Currency In USD
| Previous Close | 29.4 |
| Open | 29.63 |
| Day High | 31.7 |
| Day Low | 29.63 |
| 52-Week High | 62.53 |
| 52-Week Low | 24.1 |
| Volume | 1.33M |
| Average Volume | 840,709 |
| Market Cap | 2.91B |
| PE | -7.54 |
| EPS | -4.1 |
| Moving Average 50 Days | 30.09 |
| Moving Average 200 Days | 37.7 |
| Change | 1.52 |
If you invested $1000 in Crinetics Pharmaceuticals, Inc. (CRNX) since IPO date, it would be worth $1,261.53 as of August 23, 2025 at a share price of $30.92. Whereas If you bought $1000 worth of Crinetics Pharmaceuticals, Inc. (CRNX) shares 5 years ago, it would be worth $2,031.54 as of August 23, 2025 at a share price of $30.92.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)
GlobeNewswire Inc.
Aug 21, 2025 12:45 PM GMT
SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for atumelnant, a novel, once-daily oral adrenocortic
Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Aug 11, 2025 8:05 PM GMT
SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on August 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggre
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025
GlobeNewswire Inc.
Jul 13, 2025 9:45 PM GMT
Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label extensions of PATHFNDR-1 and PATHFNDR-2 studies Additional PALSONIFY presentations demonstrate reductions in patient-reported symptom